source
- Menarini's Stemline signs $1.1 billion deal to license Georgiamune's preclinical cancer immunotherapyGeorgiamune, a Maryland‑based immunology biotech, has granted Stemline Therapeutics, part of Italy's Menarini Group, exclusive worldwide rights to develop and commercialize its preclinical cancer c…
- FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billionThe U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company. Private-equity firm EQT announced a definit…